Skip to main content
ELAB
NASDAQ Life Sciences

PMGC Authorizes 1.5B Shares and Formalizes AI Drug Expansion Program

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$5.2
Mkt Cap
$4.121M
52W Low
$4.97
52W High
$2,671.2
52W Position info
4.6% above low
Off High info
100% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ELAB is trading near its 52-week low of $4.97 (4.6% above the low) on light trading volume (0.3× avg).

Summary

PMGC Holdings increased authorized shares to 1.5 billion and formalized a three-phase AI drug expansion program with YuvaBio, advancing four compounds toward lead nomination in cardiac disease and obesity.


Key Events · Corporate Governance and Compliance · ELAB

  • Authorized Shares Increased to 1.5 Billion

    Certificate of Amendment filed August 31, 2026 increases authorized capital stock to 1,500,000,000 shares — 1,000,000,000 common and 500,000,000 preferred — approved by holders of 60.34% of voting power.

  • Massive Dilution Headroom Created

    The new authorization gives management the ability to issue up to 1 billion common shares, vastly exceeding the current outstanding count for a company with a $4.1M market cap and a going-concern warning from its Q2 10-Q.

  • AI Expansion Program Formalized

    First Amendment to the YuvaBio license agreement launches a three-phase Expansion Program to advance all four AI-discovered compounds toward lead nomination, with fixed non-refundable fees (amount redacted) and a right of first refusal for the broader cardiometabolic field.

  • Field of Use Expanded

    Amendment clarifies NorthStrive's exclusive field of use as Cardiac Diseases and Obesity, and grants a right of first refusal to negotiate an exclusive license across the broader cardiometabolic field for one year following Phase III completion.


Analysis · ELAB · Life Sciences

PMGC Holdings increased its authorized share count to 1.5 billion shares — a massive expansion of potential dilution headroom for a company with a $4.1M market cap and a going-concern warning. The filing also formalizes a three-phase Expansion Program with YuvaBio to advance four AI-discovered compounds toward lead nomination in cardiac disease and obesity, with fixed non-refundable fees and a right of first refusal across the broader cardiometabolic field. The share authorization is the more consequential item: it gives management the ability to issue up to 1 billion common shares, far exceeding the current outstanding count, which is a red flag for a company already relying on dilutive ELOC financing.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELAB was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $4.97 to $2,671.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Nov 16, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.38 info
Change: -$0.2557 (-16%) info
Market Cap: $1.607M info
ELAB
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.38 info
Change: -$0.205 (-13%) info
Market Cap: $1.607M info
ELAB
Nov 02, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.38 info
Change: -$0.745 (-35%) info
Market Cap: $1.607M info
ELAB
Oct 01, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.62
Real-time Price: $1.38 info
Change: -$2.25 (-62%) info
Market Cap: $1.607M info
ELAB
Sep 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.70
Real-time Price: $1.38 info
Change: -$3.33 (-71%) info
Market Cap: $1.607M info